Skip to main content
SpringerLink
Log in

Different levels of TGFβ, IL-10, IFNγ and gelatinase A occur in experimental white and black metastases induced by bryostatin 1 or by phorbol ester-treated BL6T murine melanoma cells

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Bryostatin 1 and phorbol esters reduce the intracellular melanin level in high metastatic overexpressing nPKCδ BL6 (BL6T) cells, thereby inducing white experimental metastasis in syngeneic mice. We evaluate here the possible differences between white and black metastases induced by both treatments on the proliferative and metastatic potential as well as on the expression of some cytokines involved in the metastatic process such as TGFβ, IL-10 and IFNγ. The level of expression of gelatinase A is also considered. White and black metastases induced after the injection of bryostatin 1- or phorbol ester-treated cells into the tail vein of syngenic mice were isolated and analysed for the levels of LDH usually used as markers of cytotoxicity, for the levels of cytokines and gelatinase A or dissociated and cultured in vitro for a few passages. The cultured cells were analysed in vitro for the proliferative capacity and the melanin synthesis. The same cells were also re-injected into syngeneic mice and the number of experimental metastases were counted after 17 days or injected with matrigel in order to quantify the proliferative capacity in vivo. The results show only one significant difference between bryostatin 1 and phorbol ester, namely the cells obtained from white bryostatin 1-treated cells return to a black phenotype after a few passages in culture. This suggests that PKC mediates many of the biological effects of bryostatin 1 but that its effect is lost in vitro. On the other hand, white and black metastases (at least for metastases induced by BL6T cells treated with phorbol ester) do appear significantly different. In vivo white metastases show lower levels of LDH, lower levels of proliferative capacity into matrigel, higher levels of TGFβ and IFNγ and, when re-injected into syngeneic mice, give big black metastases. Therefore, in murine melanoma cells, the treatment with bryostatin 1 induces the appearance of a white population expressing different levels of TGFβ, IFNγ, IL-10 and gelatinase A. Such a white population is more difficult to diagnose and is capable of turning into a more aggressive phenotype under suitable environmental conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. La Porta CAM, Comolli R. Activation of protein kinase C-α isoform in murine melanoma cells with high metastatic potential. Clin Exp Metastasis 1997; 15: 568–79.

    Article  PubMed  CAS  Google Scholar 

  2. La Porta CAM, Comolli R. Angiogenic capacity and lung-colonising potential in vivo is increased in weakly metastatic B16F1 cells and decreased in highly metastatic BL6 cells by phorbol esters. Clin Exp Metastasis 1998; 16: 399–405.

    Article  PubMed  CAS  Google Scholar 

  3. Dennis JU, Dean NM, Bennett CF et al. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha. Cancer Lett 1998; 128: 65–70.

    Article  PubMed  CAS  Google Scholar 

  4. La Porta CAM, DiDio A, Comolli R. Overexpression of n-PKCδ in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhanced the metastatic potential in vivo. Melanoma Res 2000; 10: 93–102.

    PubMed  CAS  Google Scholar 

  5. Tsukamoto K, Gersten DM, Law LW et al. Malignant melanoma: relationship to parameters of differentaition. Melanoma Res 1991; 1: 223–30.

    PubMed  CAS  Google Scholar 

  6. Adler MJ, White CR. Amelanotic malignant melanoma. Semin Cutaneous Med Surg 1997; 16: 122–30.

    Article  CAS  Google Scholar 

  7. Mahalingam H, Vaughn J, Novotny J et al. Regulation of melanogenesis in B16 mouse melanoma cells by protein kinase C. J Cell Physiol 1996; 168: 549–58.

    Article  PubMed  CAS  Google Scholar 

  8. Hormung RL, Pearson JW, Beckwith M et al. Preclinical evaluation by bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 1992; 52: 101–7.

    Google Scholar 

  9. Shuchter LM, Esa AH, Stratford MW et al. Successful treatment of murine melanoma with bryostatin 1. Cancer Res 1991; 51: 682–7.

    Google Scholar 

  10. Prendville J, Crowther D, Thatcher N et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993; 68: 418–24.

    Google Scholar 

  11. Philip PA, Res D, Thavasu P et al. Phase I study bryostatin 1: assessment of interleukine 6 and tumor factor a induction in vivo. J Natl Cancer Inst 1993; 85: 1812–8.

    PubMed  CAS  Google Scholar 

  12. Gonzalez R, Ebbinghans S, Henthorn TK, et al. Treatment of patients with metastatic melanoma with bryostatin 1-a phase II study. Melanoma Res 1993; 9: 599–606.

    Article  Google Scholar 

  13. Whittaker JR. Changes in melanogenesis during the differentiation of chick retinal pigment cells in cell cultures. Dev Biol 1963; 8: 99–127.

    Article  CAS  Google Scholar 

  14. Englaro W, Bertolotto C, Busca R et al. Inhibition of the mitogenactivated protein kinase pathway triggers B16 melanoma cell differentiation. J Biol Chem USA 1998; 16: 9966–70.

    Article  Google Scholar 

  15. Colle J-H, Falanga PB, Singer M et al. Quantitation of messenger RNA by competitive RT-PCR: a simplified read out assay. J Immunol Methods 1997; 213: 175–84.

    Article  Google Scholar 

  16. Ailenberg M, Silverman M. Cellular activation of mesangial gelatinase A by cytochalasin D is accompanied by enhanced mRNA expression of both gelatinase A and its membrane-associated gelatinase A activator (MT-MMP). Biochem J 1996; 313: 879–84.

    PubMed  CAS  Google Scholar 

  17. Halaban R, Cheng E, Zhang YH et al. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the differentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci USA 1997; 94: 6210–5.

    Article  PubMed  CAS  Google Scholar 

  18. Arca MJ, Krauss JC, Strome SE et al. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poor immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 1996; 42: 237–45.

    Article  PubMed  CAS  Google Scholar 

  19. Szallasi Z, Du L, Levine R et al. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase Cindependent mechanism: dissociation of activities using 26-epibryostatin 1. Cancer Res 1996; 56: 2105–11.

    PubMed  CAS  Google Scholar 

  20. Martinez-Esparza, M, Jimenez-Cervantes, C, Beermann, F et al. Transforming growth factor-beta 1 inhibits basal melanogenesis in B16/F10 mouse melanoma cells by increasing the rate of degradation of tyrosinase and tyrosinase-related protein-1. J Biol Chem 1997; 272: 3967–72.

    Article  PubMed  CAS  Google Scholar 

  21. Sepp A, Binns RM, Lechler RI. Improved protocol for colorimetric detection of complement-mediated cytotoxicity based on the measurement of cytoplasmic lactate dehydrogenase activity. J Immunol Methods 1996; 196: 175–80.

    Article  PubMed  CAS  Google Scholar 

  22. Demir G, Demirelli F, Ozguroglu M et al. Immune effects of lowdose subcutaneous interleukin 2 in patients with metastatic malignant melanoma. Int J Immunother 1998; 14: 163–8.

    CAS  Google Scholar 

  23. Abdel-Wahab Z, Dar M, Osanto S et al. Eradication of melanoma polmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. Cancer Gene Ther 1997; 4: 33–41.

    PubMed  CAS  Google Scholar 

  24. Fujimoto T, Odonnell MA, Szilvasi A et al. Bacillus calmette-guerin plus interleukin-2 and/or granulocyte/macrophage-colony stimulating factor enhances immunocompetent cell production of interferongamma which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol Immunother 1996; 45: 280–4.

    Article  Google Scholar 

  25. Krasagakis K, Garbe C, Zouboulis CC et al. Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res 1995; 139: 169–82.

    PubMed  CAS  Google Scholar 

  26. Sato T, Mccue P, Masuoka K et al. Interleukine 10 production by human melanoma. Clin Cancer Res 1996; 2: 1383–90.

    PubMed  CAS  Google Scholar 

  27. Dummer W, Becker JC, Schwaaf A et al. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995: 5: 67–8.

    PubMed  CAS  Google Scholar 

  28. Huang S, Xie K, Bucana CD et al. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells, potential inhibition of angiogenesis. Clin Cancer Res 1996; 2: 1969–79.

    PubMed  CAS  Google Scholar 

  29. Hofmann UB, Westphal JR, Waas ET et al. Matrix metalloproteinases in human melanoma cell lines and xenografts:increased expression of activated matrix metalloproteinases-2 (MMP-2) correlates with melanoma progression. Br J Cancer 1999; 81: 774–82.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Physiology and Biochemistry, Section of General Pathology, University of Milan, Milan, Italy

    C.A.M. La Porta & R. Comolli

Authors
  1. C.A.M. La Porta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Comolli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

La Porta, C., Comolli, R. Different levels of TGFβ, IL-10, IFNγ and gelatinase A occur in experimental white and black metastases induced by bryostatin 1 or by phorbol ester-treated BL6T murine melanoma cells. Clin Exp Metastasis 18, 361–369 (2000). https://doi.org/10.1023/A:1010913907830

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010913907830

Search

Navigation